• news.cision.com/
  • aXichem AB/
  • aXichem: Muscletech Burn iQ containing aXivite, is now sold through world-leading American retailer GNC

aXichem: Muscletech Burn iQ containing aXivite, is now sold through world-leading American retailer GNC

Report this content

aXichem AB (publ), (aXichem), a developer of natural analogue industrial compounds, announces that the product Muscletech Burn iQ, where aXivite® is one of the active ingredients, is now available to the market through another strong sales channel, namely the world-leading American retailer GNC (General Nutrition Corporation). GNC is a leading global health and wellness brand that provides high-quality, science-based products and solutions. GNC provides its products and services worldwide through company-owned retail locations, domestic and international franchise locations, digital commerce and strong wholesale and retail partnerships across the globe. GNC presented a global yearly turnover during the years 2009 – 2019 of approximately USD 2 billion.

"It is very gratifying that Burn iQ is on the shelves and on-line at GNC and that aXivite® is clearly visible in the list of ingredients in the product. GNC is a great showcase for aXivite® and I believe the commercial potential, that comes with being on the product list of the world's largest nutritional supplement retailer, will be reflected in our revenue in 2023. It is also a great acknowledgement of our positive collaboration with Iovate Health Sciences," says Torsten Helsing, CEO of aXichem.

The North American market for nutritional supplements intended for sports and fitness is expected to grow annually by an average of just over 6% during the period 2021-2026 according to MordorIntelligence.com. The driving force for the growth is an increased awareness of health and a healthy lifestyle, but also that more training centers are being opened and that consumers' knowledge of nutritional supplements has increased.

The information was submitted, through the care of the contact person, for publication on 1 February 2023, at 15:00 CEST.

Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: torsten.helsing@axichem.se

aXichem’s business idea is to develop, patent and market natural analogue industrial compounds. The Company primarily works with phenylcapsaicin a structural analogue of capsaicin with a wide range of applications, such as feed additives, nutraceuticals and certain pharmaceutical areas. aXichem’s shares are listed on NASDAQ First North Growth Market under AXIC A. Certified Adviser: Västra Hamnen Corporate Finance, www.vhcorp.se. Read more about aXichem at www.axichem.se